A Phase 2 interventional study of ALKS 7290 Dose and Placebo in Major Depressive Disorder (MDD), sponsored by Alkermes, Inc.. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Alkermes, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Depressive Disorder, Major by Alkermes, Inc. — 1 open to participants now, 1 under way, none of them phase 3. Depressive Disorder, Major · Alkermes, Inc..
Among the 10 studies in Depressive Disorder, Major by Alkermes, Inc., this one is the 6th largest by planned enrollment, is the only one that started in 2026, is one of 2 in phase 2, and was the 10th registered.
3,050 studies on the registry are indexed under Depressive Disorder, Major; 594 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 10 studies in Depressive Disorder, Major by Alkermes, Inc. is open now, in 1 country.
By country, each count listing its studies:
Of the 415 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 295 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 7
First in 2011; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 180 is above the median of 80 across 2,536 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 229 across the 10 interventional studies. Of the 9 that completed or were terminated, 8 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
Alkermes, Inc. is the lead sponsor of 83 studies on the registry; 9 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 5 (56%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Depressive Disorder, Major by Alkermes, Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy, safety and tolerability of ALKS 7290 following oral administration in adult participants with Major Depressive Disorder.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ALKS 7290 Dose
Drug: Placebo
Daily oral ALKS 7290 with antidepressant therapy
Daily oral placebo with antidepressant therapy
Incidence of treatment-emergent adverse events
Time frame: Up to 8 weeks
Change from Baseline to Week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) total score
Time frame: Baseline to Week 6
Change in Baseline to Week 6 in Clinical Global Impression-Severity (CGI-S)
Time frame: Baseline to Week 6
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2026 (actual). Primary completion is estimated for Jan 2028, 14 months after the start.
Of 97 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's planned 14 months is below that.
Counting every sponsor, half of 196 studies reached it within 22 months; a quarter within 14 and three quarters within 37.
Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 17, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.